[Cutaneous graft-versus-host disease].
Although stem cell transplantation is a life-saving measure and the treatment of choice for many patients with various hematologic malignancies, a high incidence of complications and a transplantation associated mortality of about 30% are to be expected.Graft-versus-Host Disease (GvHD) is the major cause of morbidity and mortality after stem cell transplantation. GvHD can arise at various time points. Acute GvHD occurs during the first 100 days after transplantation in up to 50% of graft recipients, while chronic GvHD develops in about 30-50% usually within 100-500 days following allogeneic stem cell transplantation. It can involve the skin, liver, gastrointestinal tract, and less frequently the lungs, eyes and neuromuscular system. Early diagnosis of GvHD can be difficult, as drug reactions, viral infections and cutaneous reactions to radiation therapy may have clinical and histological similarities. In this review, the various cutaneous manifestations of GvHD, the histopathologic features, prophylaxis and therapy of acute and chronic GvHD are discussed in light of the recent literature.
Karrer
S
S
Klinik und Poliklinik für Dermatologie, Universität Regensburg. sigrid.karrer@klinik.uni-regensburg.de
D000328:Adult; D003937:Diagnosis, Differential; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology; D006650:Histocompatibility Testing; D006801:Humans; D015603:Keratinocytes / Q000276:immunology / Q000473:pathology; D008214:Lymphocytes / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012867:Skin / Q000276:immunology / Q000473:pathology; D012871:Skin Diseases / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous